Metabolic Research

Tirzepatide

GIP / GLP-1 dual agonist

Also known as LY3298176.

A 39-residue dual GIP and GLP-1 receptor agonist bearing a C20 fatty-diacid moiety, used in incretin-receptor and metabolic research.

Current lot: SN-TRZ-2608
Purity: 99.24% by HPLC
Tested: Aug 18, 2026
Stocked in: United States, Canada, Australia

Synamino Sciences research vial with a silver cap on a navy background

Ships from

Vial size

$59.00

USD · 10 mg · In stock

Qty

Order by 2:00 PM PT for same-day dispatch from Reno, Nevada. 1–3 business days by USPS Priority and UPS. Free shipping over $150.00.

For laboratory research use only. Not for human or veterinary use.

About the compound

Tirzepatide is built on the GIP sequence with modifications that add GLP-1 receptor activity and a fatty-acid side chain for albumin binding. It is a reference compound in dual-agonist pharmacology.

Supplied as a lyophilized powder in three vial sizes.

Studied inIncretin receptors · Glucose homeostasis models · Receptor pharmacology

Certificate of analysis

The certificate for the lot currently shipping. Every vial in that lot carries the same lot number on its label.

Earlier lots

SN-TRZ-2606Jun 5, 202699.07%

Certificate of analysis

Tirzepatide · 10 mg

Lot SN-TRZ-2608 · tested Aug 18, 2026

99.24%

Purity by HPLC

Labeled: 10 mg
Measured: 10.2 mg
Panel: 6 passed · 2 reported
Laboratory: Independent ISO/IEC 17025 accredited laboratory

Assay	Method	Result	Outcome
Appearance	Visual	White lyophilized powder	Pass
Purity	HPLC · spec ≥ 98%	99.24%	Pass
Net peptide content	HPLC	10.2 mg	Reported
Identity	LC-MS	Confirmed	Pass
Heavy metals	ICP-MS	Not detected	Pass
Sterility	USP <71>	No growth	Pass
Endotoxin	LAL · USP <85>	< 0.05 EU/mL	Reported
Residual solvents	GC-HS	Within limits	Pass

Specification and storage

CAS number: 2023788-19-2
Molecular formula: C225H348N48O68
Molecular weight: 4813.5 g/mol
Residues: 39
Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(γGlu-AEEA-AEEA-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Reference record: PubChem entry

Storage

Sealed lyophilized vials are stable at room temperature for short periods; store at 2–8 °C for routine use.
For long-term storage keep sealed vials at −20 °C, protected from light and moisture.
Reconstituted solutions should be refrigerated at 2–8 °C and used within the period defined by your laboratory's protocol.

Literature

Peer-reviewed publications on this compound. Provided for reference; they are not claims about this product.

01
Molecular Metabolism · 2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, Sloop KW, Loghin C, et al.
02
The New England Journal of Medicine · 2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al.
03
The New England Journal of Medicine · 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.

Studied alongside

Retatrutide
GIP / GLP-1 / glucagon triple agonist
from $79.00
Semaglutide
GLP-1 receptor agonist
from $49.00
Cagrilintide
Long-acting amylin analogue
from $69.00

Research notice

Tirzepatide is supplied for in vitro laboratory research and analytical use by qualified professionals. It is not a medicine, supplement or cosmetic, has not been evaluated by any regulator, and is not for human or veterinary use. Published findings cited on this page are provided for reference and are not claims about this product.